L-carnitine supplementation decreases insulin resistance, c-reactive protein in patients with chronic coronary artery disease and prostate adenocarcinoma

Abstract

Abstract Funding Acknowledgements Type of funding sources: None. The aim of the study was to evaluate the effect of L-Carnitine on the inflammation, insulin resistance (IR) in the complex therapy of patients with coronary heart disease end prostate adenocarcinoma. Materials and methods 42 men with prostate adenocarcinoma and chronic coronary heart disease (CAD) were enrolled. The patients were randomly and blindly divided into 2 groups: Group I patients were treated with L-Carnitine in addition to standard treatment; Group II patients received only conventional treatment. Standard laboratory blood tests, lipid profile, glucose, renal and liver function tests, serum C-reactive protein (CRP), insulin, echocardiographic examination were performed for all patients as baseline and after 10 days of treatment. Results IR was established in 54.8% patients of Group I and 40% patients of control group (p<0.05). In the Group I median level of HOMA index was 3.1 [1.9; 4.8] mg/ml, CRP - 10.3 [5.2; 11.1] mg/ml and decreased by 15.4% (p = 0.001) and 19.2% (p = 0.003), respectively. The supplementation of L-Carnitine in standard therapy contributed to a significant decrease in serum creatinine level and an increase in the level of GFR in Group I patients (p <0.05). Conclusion The supplementatiıon of L-Carnitine in patients with chronic coronary artery disease and prostate adenocarcinoma contributes to a significant decrease in insulin resistance, C-reactive protein level.